UNSPSC 51145201: Difemetorex

This classification denotes an anorexiant with the molecular formula C20H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) O0417MPF6W, chemically known as 1-piperidineethanol, 2-(diphenylmethyl)- but more generally known as difemetorex, which bears US NIH Compound Identifier 65607. European Medicines Agency schedules Difemetorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07118MIG.

UNSPSC 51145201 Difemetorex is a Commodity code that does not align with the state and local procurement activity currently tagged under it. The recent opportunities posted under this code—Seminole County's IFB for naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescriptions, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products—involve naloxone distribution, pharmacy benefit program design, and generic pharmaceutical supply, none of which relate to difemetorex, an anorexiant pharmaceutical. State and local governments appear to be tagging pharmaceutical procurement broadly under this code without regard to the specific drug substance the code nominally covers. The issuing bodies span county health departments (Seminole County), state health and human services agencies (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration), reflecting fragmented procurement across public health and benefits administration.

Geographic activity concentrates in Florida, Texas, and Minnesota with multistate reach through MMCAP's cooperative structure. Seminole County, Florida posted an IFB due July 26, 2023 (note: this posting date appears inconsistent with the 2026 context), requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually on a fixed-fee basis with two-year initial term and one-year renewal option. Texas HHS issued an RFI on March 27, 2026 (response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs before formal RFP issuance. MMCAP released an RFP January 20, 2026 (due March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers nationwide, with evaluation weighted heavily to price competitiveness (75 percent) and a two-year contract term effective July 1, 2026. The code shows minimal relevant recent activity; misalignment between the code name and actual procurement scope suggests vendors should verify code assignment before pursuing opportunities tagged here.